BioNano Genomics Inc vs ProShares Ultra Gold ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while ProShares Ultra Gold ETF trades at $52.3. The key difference: ProShares Ultra Gold ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | UGL | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.92 | $85.62 |
52-Week Low | $1.06 | $34.37 |
Enterprise Value | $16.26M | — |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
UGL is trading at $52.13, up 0.81% on the day, with a bullish technical signal from moving averages but overbought conditions indicated by RSI readings above 76. The stock faces immediate resistance at $52-$53 levels while finding support around $51. Recent gold market strength driven by inflation data and Fed policy expectations provides positive sector momentum.
The stock shows technical strength but requires fundamental validation through earnings reports and financial metrics. Key risks include gold price volatility and Fed policy sensitivity. Investors should monitor upcoming financial disclosures for confirmation of the current technical bullishness.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →